J Gen Virol Faster Access
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published as JGV in Press, 10.1099/vir.0.010553-0 on April 1, 2009 J Gen Virol 90 (2009), 1962-1966; DOI 10.1099/vir.0.010553-0

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary figure and table
Right arrow All Versions of this Article:
vir.0.010553-0v1
90/8/1962    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Google Scholar
Right arrow Articles by Damon, I. K.
Right arrow Articles by Karem, K.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Damon, I. K.
Right arrow Articles by Karem, K.
Agricola
Right arrow Articles by Damon, I. K.
Right arrow Articles by Karem, K.

Short Communication

Evaluation of smallpox vaccines using variola neutralization

Inger K. Damon1, Whitni B. Davidson1, Christine M. Hughes1, Victoria A. Olson1, Scott K. Smith1, Robert C. Holman1, Sharon E. Frey2, Frances Newman2, Robert B. Belshe2, Lihan Yan3 and Kevin Karem1

1 Centers for Disease Control and Prevention, National Center for Zoonotic, Vector-borne, and Enteric Diseases, Division of Viral and Rickettsial Diseases, 1600 Clifton Road NE, Atlanta, GA 30333, USA
2 Saint Louis University School of Medicine, Division of Infectious Diseases and Immunology, Edward A. Doisy Research Center, 8th Floor, 1100 S. Grand Blvd, St Louis, MO 63104, USA
3 The EMMES Corporation, 401 N. Washington St, Rockville, MD 20850, USA

Correspondence
Inger K. Damon
iad7{at}cdc.gov

The search for a ‘third’-generation smallpox vaccine has resulted in the development and characterization of several vaccine candidates. A significant barrier to acceptance is the absence of challenge models showing induction of correlates of protective immunity against variola virus. In this light, virus neutralization provides one of few experimental methods to show specific ‘in vitro’ activity of vaccines against variola virus. Here, we provide characterization of the ability of a modified vaccinia virus Ankara vaccine to induce variola virus-neutralizing antibodies, and we provide comparison with the neutralization elicited by standard Dryvax vaccination.

A supplementary figure and table are available with the online version of this paper.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
INT J SYST EVOL MICROBIOL MICROBIOLOGY J GEN VIROL
J MED MICROBIOL ALL SGM JOURNALS
Copyright © 2009 by the Society for General Microbiology.